Admilparant
Idiopathic Pulmonary Fibrosis · LPA1 Antagonist
Clinical trials
1
Mechanism
LPA1 Antagonist
Development stage
Phase III (ALOFT-IPF)
Evidence level
Level 1 (Phase III)
Developer
Bristol-Myers Squibb
Overview
Phase II: 60mg delayed disease progression vs placebo in IPF and PPF. ALOFT-IPF Phase III completing Oct 2026. Novel mechanism orthogonal to nintedanib/pirfenidone. Oral, once daily.
Admilparant clinical trials
Explore related
Medical disclaimer. This page summarizes research about Admilparant for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.